Spiro Ring System Patents (Class 514/462)
-
Patent number: 8632795Abstract: The present invention relates to a device in the form of a container made of a polymer material, which container has one or more sealed chambers, each of which comprise a liquid pheromone comprising 2-ethyl-1,6-dioxaspiro[4,4]nonane, methyl 2,4-decadiene-carboxylate and at least one alcohol selected among 2-methylbut-3-en-2-ol and 2-methylbut-3-yn-2-ol, where at least 50% of the area of the walls forming the chambers have a wall thickness in the range of from 0.1 to 1 mm and the polymer material which forms the chamber is at least in those areas an uncoated vinyl acetate/ethylene copolymer with a vinyl acetate content in the range of from 10 to 17% by weight. The invention also relates to a method of combating and for monitoring the swarming behavior of the species Pityogenes chalcographus, generally also referred to as spruce wood engraver or six-dentated bark beetle.Type: GrantFiled: November 30, 2005Date of Patent: January 21, 2014Assignee: BASF SEInventors: Thomas Zühlke, Jürgen Jentzsch, Ulf Baier, Hansjochen Schroeter
-
Patent number: 8628794Abstract: The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. It consists basically of (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) up to 9% water.Type: GrantFiled: July 29, 2004Date of Patent: January 14, 2014Assignee: Novartis AGInventor: Ute Isele
-
Patent number: 8618084Abstract: Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.Type: GrantFiled: June 8, 2009Date of Patent: December 31, 2013Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Aleksander Hinek, Thomas F. Mitts
-
Patent number: 8618096Abstract: Methods and compositions for treating disease caused by increased iron levels are disclosed Fluoregenic compounds and methods of using the same are also described.Type: GrantFiled: July 21, 2009Date of Patent: December 31, 2013Assignee: The Regents of the University of CaliforniaInventors: Adam Renslo, Sumit Mahajan
-
Publication number: 20130338222Abstract: The present invention relates to methods and compositions comprising spirodiclofen and/or spiromesifen for the control of bee mites and for the reduction of bee mite infestations, such as the control and reduction of infestations of parasitic bee mites, such as Varroa destructor in bee, preferably honey bee, colonies, and to the treatment of varroatosis in bees.Type: ApplicationFiled: September 30, 2011Publication date: December 19, 2013Applicant: SYNGENTA CROP PROTECTION LLCInventor: Andre Fougeroux
-
Publication number: 20130324580Abstract: The present invention is in the field of pharmaceuticals and chemical industries. In particular, the present invention relates to new anticancer agents based on miliusane compounds. The present invention also includes its preparation and application method for treating cancer.Type: ApplicationFiled: March 15, 2013Publication date: December 5, 2013Applicant: HONG KONG BAPTIST UNIVERSITYInventor: Hongjie ZHANG
-
Patent number: 8598225Abstract: The present invention discloses the use of L-butylphthalide of formula (I) in the manufacture of medicaments for the prevention and treatment of cerebral infarct, especially induced by focal cerebral ischemia.Type: GrantFiled: October 20, 2010Date of Patent: December 3, 2013Assignee: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.Inventors: Yipu Feng, Xiaoliang Wang, Jinghua Yang, Ying Peng
-
Patent number: 8586112Abstract: The invention provides a process for the production of a substance or composition for the treatment, by therapy or prophylaxis, of parasitic infections, in particular malarial infections such as Plasmodium falciparum infections, of the human or animal body. The process comprises extracting the substance or composition from roots of the plant species Dicoma anomala, by an extraction using an organic solvent to obtain a liquid extract containing the substance or composition and removing the solvent from the liquid extract to leave a dried extract containing the substance or composition. The invention extends also to the use of the substance or composition in the manufacture of a medicament or preparation for such treatment of infections; to a substance or composition for use in such treatment of said infections; to compounds for use in such treatment of said infections; and to a method of treating said infections using such compounds.Type: GrantFiled: November 2, 2005Date of Patent: November 19, 2013Assignees: South African Medical Research Council, University of Cape TownInventors: Motlalepula Gilbert Matsabisa, William Ernest Campbell, Peter Ian Folb, Peter John Smith
-
Publication number: 20130295190Abstract: The present disclosure provides improved systems and methods utilizing colloidal/ultrafine superdisintegrant-based composite particles for dispersion and/or dissolution of active pharmaceutical agents. In general, the present disclosure utilizes a surfactant-free or near surfactant-free formulation by incorporating a wet milled SDI as a dispersant in the formulation. As such, the present disclosure provides for the preparation of surfactant-free or substantially surfactant-free formulations (e.g., nano-composite micro-particle formulations) by incorporating a wet-milled superdisintegrant (SDI) as the dispersant in the formulations. The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles) of the present disclosure can be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents (e.g. poorly water-soluble drugs) in the formulations (e.g.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Applicant: New Jersey Institute of TechnologyInventors: Ecevit Bilgili, Rajesh Dave, Anagha Bhakay, Mohammad Azad
-
Patent number: 8563603Abstract: The invention relates to a novel compound of formula I or pharmaceutically acceptable salts thereof as well as pharmaceutical, nutraceutical, and botanical drug compositions and therapeutic methods related thereto. In certain embodiments, the compounds are used for the treatment of abnormal cell growth, hyperproliferative disorders, and inflammatory diseases in mammals. In other embodiments, the invention encompasses methods to isolate and synthesize the compounds.Type: GrantFiled: October 22, 2009Date of Patent: October 22, 2013Assignee: Cornell UniversityInventors: Kathryn J. Chavez, Eloy Rodriguez, Frank Schroeder, James A. Flanders
-
Patent number: 8563714Abstract: The present invention relates to bridged spiro[2.4]heptane derivatives of formula (I), wherein W, Y, Z, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds as ALX receptor and/or FPRL2 agonists for the treatment of inflammatory and obstructive airways diseases.Type: GrantFiled: May 17, 2010Date of Patent: October 22, 2013Assignee: Actelion Pharmaceuticals Ltd.Inventors: Daniel Bur, Olivier Corminboeuf, Sylvaine Cren, Corinna Grisostomi, Xavier Leroy, Sylvia Richard-Bildstein
-
Publication number: 20130273025Abstract: This invention provides an oral veterinary pharmaceutical or nutraceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion further comprising at least one component selected from taste enhancers, odour enhancers, digestive enzymes and veterinary drugs.Type: ApplicationFiled: April 11, 2011Publication date: October 17, 2013Applicant: AYANDA GROUP ASInventors: Kurt Ingar Draget, Ingvild Johanne Haug, Steinar Johan Engelsen, Tore Seternes
-
Patent number: 8541019Abstract: The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. It consists basically of (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) up to 9% water.Type: GrantFiled: October 31, 2011Date of Patent: September 24, 2013Assignee: Novartis AGInventor: Ute Isele
-
Patent number: 8536196Abstract: Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.Type: GrantFiled: January 18, 2008Date of Patent: September 17, 2013Assignee: Evolva SAInventors: Alexandra Santana Sorensen, Jean-Philippe Meyer, Peteris Alberts, Prathama S. Mainkar, Melya Hughes Crameri, Thierry Bonnaud, Joanne Kelleher, David Pearson
-
Publication number: 20130231311Abstract: Systems and methods are described for treating un-met medical needs in migraine and related conditions such as cluster headache. Included are treatments that are both rapid onset and long acting, which include sustained release formulations, and combination products. Also included are treatments for multiple symptoms of migraine, especially headache and nausea and vomiting. Systems that are self contained, portable, prefilled, and simple to self administer at the onset of a migraine attack are disclosed, and preferably include a needle-free injector and a high viscosity formulation, to eliminate such issues as fear of self administration with needles, and needle stick and cross contamination.Type: ApplicationFiled: April 16, 2013Publication date: September 5, 2013Inventors: Stephen J. FARR, John TURANIN, Roger HAWLEY, Jeffrey A. SCHUSTER
-
Publication number: 20130203718Abstract: The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.Type: ApplicationFiled: May 9, 2011Publication date: August 8, 2013Inventors: Marie-Edith Rafestin-Oblin, Mouad Alami, Hugues Loosfelt, Abdallah Hamze, Ali Junaid Khan, Abdellatif Tikad, Marc Lombes, Jean-Daniel Brion
-
Patent number: 8486995Abstract: Disclosed is a method of controlling insects or acarids comprising contacting crops or their environment with a compound of the formula (I): and least one compound selected from the group consisting of: bifenazate, fenpyroximate pyridaben, fenazaquin, abamectin, emamectin benzoate, fenpropathrin and propargite.Type: GrantFiled: June 27, 2008Date of Patent: July 16, 2013Assignee: Bayer CorporationInventors: Reiner Fischer, Emmanuel Salmon, Heike Hungenberg, Jingquan Guo
-
Patent number: 8487121Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.Type: GrantFiled: December 16, 2008Date of Patent: July 16, 2013Assignee: Glenmark Pharmaceuticals S.A.Inventors: V S Prasadarao Lingam, Abraham Thomas, Laxmikant Atmaram Gharat, Deepak Vitthal Ukirde, Shantaram Kashinath Phatangare, Ajit Shankar Mindhe, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
-
Patent number: 8470774Abstract: Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.Type: GrantFiled: February 27, 2012Date of Patent: June 25, 2013Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Aleksander Hinek, Thomas F. Mitts
-
Patent number: 8445532Abstract: Phthalide derivatives and the use of which to manufacture the sensitizer or reverser of the antineoplastic agent are described. The phthalide derivatives can enhance the sensitivity of drug-resistance tumor cells against chemotherapy and decrease the drug-resistance of tumor cells 5-30 folder and enhance notably several chemotherapy agents-induced apoptosis of tumor cells.Type: GrantFiled: September 30, 2005Date of Patent: May 21, 2013Inventors: Fei Chen, Tao Wang
-
Publication number: 20130115165Abstract: Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropylacrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral; either water-soluble vinyl derivatives like vinylpryolidone (VP) or vinyl acetate (VA), or water insoluble vinyl derivaties like methyl methacrylate (MMA) or styrene (ST), at a molar ratio of about 10% to about 30%; and acrylic acid (AA), at a molar ration of about 10% to about 30%.Type: ApplicationFiled: October 12, 2012Publication date: May 9, 2013Inventors: Anirban Maitra, Georg Feldmann, Savita Bisht
-
Publication number: 20130115249Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and/or the drug-containing coat.Type: ApplicationFiled: July 18, 2012Publication date: May 9, 2013Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Juan A. VERGEZ, Joaquina FAOUR, Ana C. PASTINI, Guido S. BIGATTI, Glenn A. MEYER, Ethel C. FELEDER, Marcelo A. RICCI, Marcelo A. COPPARI, Marcelo F. BEFUMO
-
Patent number: 8420608Abstract: The novel active compound combinations comprising compounds of the formula (I) and spinetoram have very good insecticidal and/or acaricidal properties.Type: GrantFiled: November 13, 2009Date of Patent: April 16, 2013Assignee: Bayer Cropscience AGInventors: Reiner Fischer, Wolfram Andersch, Heike Hungenberg
-
Publication number: 20130052248Abstract: An item of clothing (10) for daily pharmacological treatment of a fungal infection, comprising: a textile material (20) to manage moisture when the item of clothing (10) is worn; microcapsules (30) grafted on the textile material (20); and antifungal agents encapsulated within the microcapsules (30) to pharmacologically treat the fungal infection when released from the microcapsules (30).Type: ApplicationFiled: August 26, 2011Publication date: February 28, 2013Inventors: Marcus Chun Wah YUEN, Joanne Yiu Wan YIP, Kevin CHEUK, Chi Wai KAN, Shuk Yan CHENG
-
Publication number: 20130040935Abstract: The invention relates to 5?-biphenyl-substituted cyclic ketoenols for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumour disorders.Type: ApplicationFiled: February 8, 2011Publication date: February 14, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ningshu Liu, Kai Thede, Philip Lienau, Arne Scholz, Christoph-Stephan Hilger, Ulf Bömer, Maher Najjar, Knut Eis, Reiner Fischer, Wahed Ahmed Moradi
-
Publication number: 20130014428Abstract: Disclosed are methods which include exposing a beetle of the species Pityophthorus juglandis and/or treating surfaces susceptible to infestation by the species or to infection by Geosmithia morbida with compositions including one or more semiochemicals capable of being produced by Pityophthorus juglandis. The semiochemicals can be 3-methyl-2-buten-1-ol, conophthorin or chalcogran. Also disclosed are compositions and systems used in the methods.Type: ApplicationFiled: July 13, 2012Publication date: January 17, 2013Applicant: The United States of America as Represented by the Secretary of AgricultureInventors: Steven J. Seybold, Paul L. Dallara, Lori J. Nelson, Andrew D. Graves, Stacy M. Hishinuma, Regine Gries
-
Patent number: 8349890Abstract: The present invention refers to 5,7-dioxatetracyclo[9.2.1.01.9,04.8]tetradecane derivatives of formula I wherein R1-R3 have the same meaning as given in the description. The invention furthermore refers to their preparation and to perfume compositions and fragrance applications comprising them.Type: GrantFiled: June 29, 2009Date of Patent: January 8, 2013Assignee: Givaudan S.A.Inventors: Jerzy A. Bajgrowicz, Christopher Furniss
-
Publication number: 20120328679Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment.Type: ApplicationFiled: September 7, 2012Publication date: December 27, 2012Inventors: William J. Curatolo, Scott M. Herbig, James A. S. Nightingale
-
Publication number: 20120329865Abstract: Disclosed are compounds having structural formula (I, II) or a pharmaceutically acceptable sale, solvate, clathrate, or prodrug thereof, wherein R1, R2, R3, R6, R5, and R4 are defined herein. These compounds can be useful as therapeutic agents for modulating hERG ion channels, and for improving prevention and treatment of hERG associated cardiac repolarization disorders.Type: ApplicationFiled: December 16, 2010Publication date: December 27, 2012Inventors: Huayun Deng, Ye Fang, Ann MeeJin Ferrie, Mingqian He, Weijun Niu, Haiyan Sun, Elizabeth Tran, Ying Wei
-
Publication number: 20120252870Abstract: Methods of diagnosing osteoarthritis are carried out by measuring levels of Ihh, and methods of treating osteoarthritis comprise inhibiting Ihh to reduce or prevent cartilage degradation.Type: ApplicationFiled: February 17, 2012Publication date: October 4, 2012Inventor: Lei Wei
-
Patent number: 8273790Abstract: This application discloses a novel process for the synthesis of himbacine analogs, as well as the compounds produced thereby. The synthesis proceeds by alternative routes including the cyclic ketal amide route, the chiral carbamate amide route, and the chiral carbamate ester route. The compounds produced thereby are useful as thrombin receptor antagonists.Type: GrantFiled: February 10, 2012Date of Patent: September 25, 2012Assignee: Schering CorporationInventors: Tiruvettipuram K. Thiruvengadam, Anantha Sudhakar, Ngiap Kie Lim, Daw-Iong Kwok, George G. Wu, Tao Wang, Mingsheng Huang, Michael D. Green
-
Patent number: 8247579Abstract: The present invention relates to novel spirocyclic tetronic acid derivatives of the formula (I) in which R1, R2 and R3 have the meanings given in the description, to a plurality of processes for their preparation and to their use as pesticides.Type: GrantFiled: January 9, 2008Date of Patent: August 21, 2012Assignee: Bayer Cropscience AGInventors: Reiner Fischer, Thomas Bretschneider, Hubertus Schulte, Gerhard Krautstrunk, Christian Arnold, Erich Sanwald
-
Patent number: 8247444Abstract: The present invention provides for the use of a dimeric phthalide compound, the dimeric phthalide compound has broad anti-tumor activity, can directly inhibit the proliferation of tumor cells and induce cell death, but also indirectly inhibit the development of tumors by suppressing neovascularization. And further, the dimeric phthalide compound can be used alone or in combination to treat cancer, as well as in combination with chemotherapeutics to increase the efficacy of chemotherapeutics and decrease the toxicity of chemotherapeutics.Type: GrantFiled: January 19, 2007Date of Patent: August 21, 2012Inventors: Fei Chen, Tao Wang, Yifeng Wu
-
Patent number: 8222288Abstract: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).Type: GrantFiled: June 14, 2010Date of Patent: July 17, 2012Assignee: The Regents of the University of MichiganInventors: Shaomeng Wang, Dongguang Qin, Jianyong Chen, Shanghai Yu
-
Patent number: 8216971Abstract: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on propamocarb-HCl, an insecticide active substance and optionally a further fungicide active substance.Type: GrantFiled: December 21, 2007Date of Patent: July 10, 2012Assignee: Bayer Intellectual Property GmbHInventors: Koen van Den Eynde, Wolfgang Thielert, Heike Hungenberg
-
Publication number: 20120157519Abstract: Tellurium-containing compounds identified for use in a method of treating, or prophylaxis against, a viral infection caused by an influenza virus, uses thereof and pharmaceutical kits and pharmaceutical corn positions comprising the same, are disclosed. The tellurium-containing compounds disclosed herein are suitable for co-administration with an antiviral agent.Type: ApplicationFiled: June 16, 2010Publication date: June 21, 2012Applicant: Biomas Ltd.Inventors: Benjamin Sredni, Michael Albeck
-
Publication number: 20120129833Abstract: The invention relates to 5?-biphenyl-substituted cyclic ketoenols for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of diabetes, obesity, hyperlipidaemia, fatty livers and of disorders of the cardiovascular system.Type: ApplicationFiled: August 19, 2011Publication date: May 24, 2012Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ningshu LIU, Kai Thede, Philip Lienau, Arne Scholz, Maher Najjar, Ulf Bomer, Knut Eis, Reiner Fischer
-
Publication number: 20120129818Abstract: Ortho methoxy phenolic compounds are provided that include methylenedioxyphenyl ferulate and ferulylproline and derivatives thereof. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating cardiovascular diseases, including hypertension, atherosclerosis, coronary heart disease, angina, stroke, and myocardial infarction, are further provided. The compounds are also useful in reducing low-density lipoprotein oxidation, improving or increasing vasodilation, and reducing plaque destabilization in a subject.Type: ApplicationFiled: April 23, 2010Publication date: May 24, 2012Inventor: Desikan Rajagopal
-
Publication number: 20120115841Abstract: The present invention relates to bridged spiro[2.4]heptane derivatives of formula (I), wherein W, Y, Z, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds as ALX receptor and/or FPRL2 agonists for the treatment of inflammatory and obstructive airways diseases.Type: ApplicationFiled: May 17, 2010Publication date: May 10, 2012Applicant: ACTELION PHARMACEUTICALS LTD.Inventors: Daniel Bur, Olivier Corminboeuf, Sylvaine Cren, Corinna Grisostomi, Xavier Leroy, Sylvia Richard-Bildstein
-
Publication number: 20120114574Abstract: Novel topical compositions for the treatment of nail and skin afflictions comprising at least one active agent, at least one volatile solvent, at least one film-forming ingredient and at least one phospholipid, processes for their preparation and methods of treatment of nail and skin afflictions. Following application of the compositions and evaporation of volatile solvents, the composition produces a film, which has web-like structures containing the active agent(s).Type: ApplicationFiled: August 1, 2011Publication date: May 10, 2012Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventor: Elka Touitou
-
Publication number: 20120094939Abstract: The present invention is directed to compounds of formulae (I) and (II) and pharmaceutically acceptable forms thereof; pharmaceutical compositions thereof; and methods of treating a viral infection, such as a hepatitis C virus (HCV) infection, by administering to a subject diagnosed with or being susceptible to the viral infection a compound of formulae (I) and (II), a pharmaceutically acceptable form thereof, or a pharmaceutical composition thereof. The present invention is also directed to high-throughput methods of identifying compounds able to modulate hepatitis C virus (HCV) replication activity.Type: ApplicationFiled: April 4, 2008Publication date: April 19, 2012Inventors: Stuart L. Schreiber, Raymond T. Chung, Lee F. Peng, Sun Suk Kim, Sirinya Matchacheep, John A. Porco, JR., Aaron B. Beeler
-
Patent number: 8158791Abstract: A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH2)m2-, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R6, R7 and R8 independently represent a lower alkyl group or the like].Type: GrantFiled: November 10, 2006Date of Patent: April 17, 2012Assignee: MSD K.K.Inventors: Makoto Jitsuoka, Nagaaki Sato, Daisuke Tsukahara
-
Patent number: 8148327Abstract: Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.Type: GrantFiled: June 6, 2008Date of Patent: April 3, 2012Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Thomas Mitts, Aleksander Hinek
-
Publication number: 20120077767Abstract: Methods for identifying fungal infection, assays for identifying genomic and protein markers of fungal infection, and methods for diagnosing the fungal infection. In one aspect, the method of identifying fungal infection by proteomic assay involves measuring the protein levels of proteins listed in Table 2A in a peripheral blood cell sample and comparing the determined protein levels to standard protein levels. In another aspect, subjects identified as being infected with fungal infection are treated with anti-fungals.Type: ApplicationFiled: May 26, 2010Publication date: March 29, 2012Inventors: Aimee K. Zaas, Geoffrey S. Ginsburg, Joseph Lucas, Hamza Aziz, John R. Perfect
-
Patent number: 8138119Abstract: The invention relates to novel alkoxyalkyl spirocyclic tetramic and tetronic acids of the formula (I), in which A, B, D, Q1, Q2, Q3, Q4, G, W, X, Y and Z are as defined above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides and/or microbicides, and also to selective herbicidal compositions comprising, firstly, the alkoxyalkyl spirocyclic tetramic and tetronic acids and, secondly, at least one crop plant compatibility-improving compound.Type: GrantFiled: October 20, 2006Date of Patent: March 20, 2012Assignee: Bayer Cropscience AGInventors: Reiner Fischer, Oliver Gaertzen, Stefan Lehr, Dieter Feucht, Olga Malsam, Mark Wilhelm Drewes, Eva-Maria Franken, Christian Arnold, Thomas Auler, Martin Jeffrey Hills, Heinz Kehne, Chris Hugh Rosinger, Thomas Bretschneider, Guido Bojack, Jan Dittgen
-
Publication number: 20120058199Abstract: The present invention provides the use of surface active proteins, especially class I and class II hydrophobins, in topically applied pharmaceutical formulations. The invention is particularly directed to topically applied pharmaceutical products for enhancing the penetration to achieve a transungual delivery of a prophylactically and/or therapeutically effective amount of an active ingredient (drug) to a patient (including animals and humans) into and/or through a nail, of the animal or human body, in order to treat one or more of a variety of diseases or disorders. Related embodiments of the invention are also disclosed.Type: ApplicationFiled: February 19, 2010Publication date: March 8, 2012Applicant: BASF SEInventors: Andreas Buthe, Andreas Hafner, Franz Kaufmann, Babette Fiedler, Guido Meurer, Gordon Bradley
-
Publication number: 20120046264Abstract: Methods for commercial production of transdermal formulations comprising a hormone compound are provided. In particular, methods for commercial scale production under an inert atmosphere of a transdermal formulation comprising a therapeutically effective amount of a hormone, preferably a testosterone compound, useful for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women are provided.Type: ApplicationFiled: August 17, 2011Publication date: February 23, 2012Applicant: BIOSANTE PHARMACEUTICALS, INC.Inventors: Stephen Simes, Linda Lieb
-
Publication number: 20120035200Abstract: The invention relates to compounds of the formula (I), where the symbols have the meaning given in the specification, for use in a method for treating cancer, to use of these compounds for the manufacture of a pharmaceutical composition for the treatment of cancer, and to methods of treatment for said diseases employing a compound of formula (I).Type: ApplicationFiled: December 22, 2009Publication date: February 9, 2012Applicant: Deutsches Krebsforschungszentrum Stiftung des offentlichen RechtsInventors: Alwin Kraemer, Blanka Leber, Mads Clausen, Thomas Larsen, Mads Roennest, Kasper Worm
-
Patent number: 8105979Abstract: The present invention relates to novel active compound combinations comprising at least one known compound from the class of the tetronic or tetramic acids and at least one further known active compound of the formula (I) in which R is as defined in the description. Combinations of the present invention are highly suitable for controlling animal pests such as insects and unwanted acarids.Type: GrantFiled: March 19, 2007Date of Patent: January 31, 2012Assignee: Bayer CropScience AGInventors: Heike Hungenberg, Peter Jeschke, Reiner Fischer, Robert Velten, Thomas Schenke, Wolfram Andersch, Wolfgang Thielert
-
Patent number: RE43858Abstract: A compound of formula (I) Wherein X, Y, ring A, ring B, l, m, R1, R2, R4 and R5 are as defined herein, to supress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-?, pharmacologically acceptable salts therefor, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation.Type: GrantFiled: September 13, 2006Date of Patent: December 11, 2012Assignee: Daiichi Sankyo Company, LimitedInventors: Tomio Kimura, Nobuyuki Ohkawa, Takayoshi Nagasaki, Atsuhiro Sugidachi, Osamu Ando